action of TRAIL Biopharmaceuticals
Discovery of anticancer polymeric drugs
innovative PolyDrug discovery process
start-up PolyDrug discovery company
modern drug discovery process
high affinity
high-throughput screening
polymeric replacements
greatest anticancer potential
current biopharmaceuticals
lead optimization
output capacity
cell studies
binding epitopes
ligand
WP1
activity of tumor necrosis factor-related apoptosis
production costs
macromolecular modeling
monoclonal antibodies
clinical development
interferons
demanding storage conditions
mAbs
peptides
Work Package
death receptor
approval of recombinant human insulin
cytokines
WP2
DR5
combinatorial polymer chemistry
library preparation
multivalent polymers
challenges
treatment of breast cancer
efforts
PolyDrugs
scope
objective